Amneal Pharmaceuticals Stockholders Approve Acquisition of Kashiv BioSciences

Amneal Pharmaceuticals (AMRX) announced that its stockholders have approved all necessary proposals related to its planned acquisition of 100% of the membership interests in Kashiv BioSciences, LLC. The approvals, granted at a special meeting on July 31, 2026, clear a key condition for the transaction's completion.

Key Details

• Acquisition Approval: Stockholders voted to approve the Membership Interest Purchase Agreement, dated April 21, 2026, for Amneal to acquire Kashiv BioSciences.
• Stock Issuance: The issuance of 28,942,108 shares of Class A Common Stock to Kashiv's equityholders as part of the transaction was also approved.
• Expected Closing: The acquisition is now expected to close in the second half of 2026, subject to the satisfaction of remaining closing conditions.